Trecadrine () is a drug that was originally developed as an anti-ulcer agent but was found to act as a ò<sub>3</sub>-adrenergic receptor agonist with potential anti-obesity and anti-diabetic properties. It is selective for the ò<sub>3</sub>-adrenergic receptor, lacking activity at the ò<sub>1</sub>- and ò<sub>2</sub>-adrenergic receptors. The drug is orally active. Structurally, trecadrine is a substituted ò-hydroxyamphetamine and derivative of ò-hydroxy-N-methylamphetamine (ephedrine, pseudoephedrine) with a tricyclic moiety attached at the amine.